Ki-67 Expression is a Prognostic Marker of Prostate Cancer Recurrence after Radical Prostatectomy

Abstract

No AccessJournal of UrologyClinical Urology: Original Article1 Sep 1996Ki-67 Expression is a Prognostic Marker of Prostate Cancer Recurrence after Radical Prostatectomy Marie-Claude Bettencourt, John J. Bauer, Isabell A. Sesterhenn, F.K. Mostofi, DAvid G. McLeod, and Judd W. Moul Marie-Claude BettencourtMarie-Claude Bettencourt , John J. BauerJohn J. Bauer , Isabell A. SesterhennIsabell A. Sesterhenn , F.K. MostofiF.K. Mostofi , DAvid G. McLeodDAvid G. McLeod , and Judd W. MoulJudd W. Moul View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)65703-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed the cellular proliferation of clinically localized prostate cancer by immunohistochemistry using the monoclonal antibody MIB to Ki-67 antigen in an attempt to identify associations between proliferative indexes and disease progression following radical prostatectomy. Materials and Methods: Ki-67 proliferative antigen was evaluated using MIB 1 monoclonal antibody in archival paraffin embedded radical prostatectomy specimens from 180 patients followed for 1 to 9 years (mean 4.4). The percentage of tumor nuclei expressing Ki-67 antigen was measured and assigned an MIB 1 score (none or rare-negative, 1+-low score and 2 to 4+-high score) and analyzed for prostate specific antigen, stage, age, race, grade and serological recurrence postoperatively. Results: There was a significant association between MIB 1 score and nuclear grade (p less than 0.001), Gleason score (p less than 0.001) and pathological stage (p = 0.01). Patients with a high MIB 1 score had earlier progression and a lower 5-year recurrence-free survival rate (44 percent) than those with negative MIB 1 scores (71 percent, p less than 0.001). In multivariate Cox regression analysis with backward elimination, pathological stage (p less than 0.01), pretreatment prostate specific antigen (p = 0.04) and MIB 1 score (p = 0.05) were statistically significant predictors of disease-free survival, and patients with a high MIB 1 score were 3.1 times as likely to have recurrence as those with a negative score. Controlling for stage, patients with organ confined disease and a high MIB 1 score had a lower 5-year disease-free survival rate (68 percent) than those with a low MIB 1 score (95 percent, p greater than 0.01). Conclusions: Proliferative activity as measured by the Ki-67 proliferative antigen, MIB 1, appears to be a prognostic marker of recurrent prostate cancer after radical prostatectomy. References 1 : Cancer statistics, 1994. CA1994; 44: 7. Google Scholar 2 : An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. J.A.M.A.1993; 269: 2633. Google Scholar 3 : A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch. Fam. Med.1993; 2: 487. Google Scholar 4 : Monoclonal antibody Ki-67: its use in histopathology. Histopathology1990; 17: 489. Crossref, Medline, Google Scholar 5 : Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol.1984; 133: 1710. Google Scholar 6 : Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression. Prostate1995; 26: 87. Google Scholar 7 : Monoclonal antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer. J. Urol.1989; 142: 1342. Link, Google Scholar 8 : Growth fractions in human prostatic carcinoma determined by the Ki-67 immunostaining. J. Path.1988; 156: 161. Google Scholar 9 : Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the proliferative cell fraction of human prostatic carcinoma. J. Urol.1991; 145: 81. Link, Google Scholar 10 : Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Brit. J. Urol.1993; 72: 92. Google Scholar 11 : Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer1991; 67: 3065. Google Scholar 12 : Ki-67 expression and BrdUrd incorporation as markers of proliferative activity in human prostate tumour models. Cell Prolif.1993; 26: 67. Google Scholar 13 : Monoclonal antibody against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Path.1992; 168: 357. Google Scholar 14 : The clinical usefulness of prostate specific antigen. Update 1994. J. Urol.1994; 152: 1358. Abstract, Google Scholar 15 : Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by . Philadelphia: Lea & Febiger1977: 171. chapt. 9. Google Scholar 16 : Histological Typing of Prostate Tumours. Geneva: World Health Organization1980. Google Scholar 17 : The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clinicopathologic correlations. Cancer1994; 74: 104. Crossref, Medline, Google Scholar 18 : p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res.1995; 1: 1295. Google Scholar 19 : Implication of cell kinetic changes during the progression of human prostate cancer. Clin. Cancer Res.1995; 1: 473. Google Scholar 20 : Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J. Urol.1982; 128: 1353. Link, Google Scholar 21 : S-phase fraction of human prostate adenocarcinoma studies with in vivo bromodeoxyuridine labeling. Cancer1990; 66: 509. Google Scholar 22 : Pathological and clinical associations of Ki-67 defined growth fractions in human prostatic carcinoma. Prostate1992; 21: 75. Google Scholar 23 : Determination of Ki-67 defined growth fraction by monoclonal antibody MIB-1 in formalin-fixed, parrafin-embedded prostatic cancer tissues. Prostate1995; 27: 154. Google Scholar 24 : Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol.1988; 139: 766. Link, Google Scholar 25 : The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol.1993; 150: 110. Link, Google Scholar 26 : A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J. Urol.1995; 154: 131. Link, Google Scholar 27 : Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology1995; 45: 831. Google Scholar 28 : Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. N. Amer.1993; 20: 713. Google Scholar 29 : Cancer statistics for African Americans. CA1992; 42: 7. Google Scholar 30 : Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. J.A.M.A.1995; 274: 1277. Crossref, Medline, Google Scholar From the Urology Service, and Departments of Surgery and Clinical Investigation, Walter Reed Army Medical Center and Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, D. C., and Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of Health Sciences, Bethesda, Maryland.© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMOUL J, CONNELLY R, LUBECK D, BAUER J, SUN L, FLANDERS S, GROSSFELD G and CARROLL P (2018) PREDICTING RISK OF PROSTATE SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY WITH THE CENTER FOR PROSTATE DISEASE RESEARCH AND CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR DATABASESJournal of Urology, VOL. 166, NO. 4, (1322-1327), Online publication date: 1-Oct-2001.ISOLA J, AUVINEN A, POUTIAINEN M, KAKKOLA L, JÄRVINEN T, MÄÄTTÄNEN L, STENMAN U, TAMMELA T, HAKAMA M and VISAKORPI T (2018) PREDICTORS OF BIOLOGICAL AGGRESSIVENESS OF PROSTATE SPECIFIC ANTIGEN SCREENING DETECTED PROSTATE CANCERJournal of Urology, VOL. 165, NO. 5, (1569-1574), Online publication date: 1-May-2001.VIS A, NOORDZIJ M, FITOZ K, WILDHAGEN M, SCHRÖDER F and van der KWAST T (2018) PROGNOSTIC VALUE OF CELL CYCLE PROTEINS p27kip1 AND MIB-1, AND THE CELL ADHESION PROTEIN CD44s IN SURGICALLY TREATED PATIENTS WITH PROSTATE CANCERJournal of Urology, VOL. 164, NO. 6, (2156-2161), Online publication date: 1-Dec-2000.LEIBOVICH B, CHENG L, WEAVER A, MYERS R and BOSTWICK D (2018) OUTCOME PREDICTION WITH p53 IMMUNOSTAINING AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCERJournal of Urology, VOL. 163, NO. 6, (1756-1760), Online publication date: 1-Jun-2000.MOUL J (2018) PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCERJournal of Urology, VOL. 163, NO. 6, (1632-1642), Online publication date: 1-Jun-2000.RITTMASTER R, THOMAS L, WRIGHT A, MURRAY S, CARLSON K, DOUGLAS R, YUNG J, MESSIEH M, BELL D and LAZIER C (2018) THE UTILITY OF TISSUE TRANSGLUTAMINASE AS A MARKER OF APOPTOSIS DURING TREATMENT AND PROGRESSION OF PROSTATE CANCERJournal of Urology, VOL. 162, NO. 6, (2165-2169), Online publication date: 1-Dec-1999.BETTENCOURT M, BAUER J, SESTERHENN I, CONNELLY R and MOUL J (2018) CD34 IMMUNOHISTOCHEMICAL ASSESSMENT OF ANGIOGENESIS AS A PROGNOSTIC MARKER FOR PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMYJournal of Urology, VOL. 160, NO. 2, (459-465), Online publication date: 1-Aug-1998.CASELLA R, BUBENDORF L, SAUTER G, MOCH H, MIHATSCH M and GASSER T (2018) FOCAL NEUROENDOCRINE DIFFERENTIATION LACKS PROGNOSTIC SIGNIFICANCE IN PROSTATE CORE NEEDLE BIOPSIESJournal of Urology, VOL. 160, NO. 2, (406-410), Online publication date: 1-Aug-1998.BORRE M, BENTZEN S, NERSTROM B and OVERGAARD J (2018) TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLYJournal of Urology, VOL. 159, NO. 5, (1609-1614), Online publication date: 1-May-1998.MOUL J, CONNELLY R, PERAHIA B and MCLEOD D (2018) THE CONTEMPORARY VALUE OF PRETREATMENT PROSTATIC ACID PHOSPHATASE TO PREDICT PATHOLOGICAL STAGE AND RECURRENCE IN RADICAL PROSTATECTOMY CASESJournal of Urology, VOL. 159, NO. 3, (935-940), Online publication date: 1-Mar-1998.BAUER J, CONNELLY R, SETERHENN I, DEAUSEN J, SRIVASTAVA S, MCLEOD D and MOUL J (2018) BIOSTATISTICAL MODELING USING TRADITIONAL PREOPERATIVE AND PATHOLOGICAL PROGNOSTIC VARIABLES IN THE SELECTION OF MEN AT HIGH RISK FOR DISEASE RECURRENCE AFTER RADICAL PROSTATECTOMY FOR PROSTATE CANCERJournal of Urology, VOL. 159, NO. 3, (929-933), Online publication date: 1-Mar-1998.Stattin P, Damber J, Karlberg L and Bergh A (2018) Cell Proliferation Assessed by Ki-67 Immunoreactivity on Formalin Fixed Tissues is a Predictive Factor for Survival in Prostate CancerJournal of Urology, VOL. 157, NO. 1, (219-222), Online publication date: 1-Jan-1997. Volume 156Issue 3September 1996Page: 1064-1068 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information Marie-Claude Bettencourt More articles by this author John J. Bauer More articles by this author Isabell A. Sesterhenn More articles by this author F.K. Mostofi More articles by this author DAvid G. McLeod More articles by this author Judd W. Moul More articles by this author Expand All Advertisement PDF downloadLoading ...